8507 Background: In the majority of patients with relapsed or refractory Hodgkin Lymphoma (HL) Brentuximab vedotin (BV) has shown significant activity, with a manageable safety profile. We aimed to assess the role of 2 cycles of BV before starting the standard treatment with ABVD +/- RT in patients with previously untreated HL. Methods: Patients with previously untreated CD30-positive HL, stage IA or IIA or IIIA, absence of bulky disease, defined as a mediastinal mass greater than one-third of the maximum chest diameter, or any other mass greater than or equal to 10 cm, received 2 cycles of BV 1.8 mg/Kg intravenously every 3 weeks over 30 minutes, as an outpatient infusion, followed by 3-6 cycles of ABVD depending on stage. Decision on radiotherapy was at physician’s discretion. The primary endpoint of the study was the response to BV assessed by FDG/PET, defined as reduction of Deauville score or, in case of no change in Deauville score, as any reduction in SUV intensity compared to basal SUV. PET result...